Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials

被引：52
|
作者：
Choi, I. [2 ]
Tanosaki, R. [3 ]
Uike, N. [2 ]
Utsunomiya, A. [4 ]
Tomonaga, M. [5 ]
Harada, M. [6 ]
Yamanaka, T.
Kannagi, M. [7 ]
Okamura, J. [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Inst Clin Res, Minami Ku, Fukuoka 8111395, Japan
[2] Kyushu Natl Canc Ctr, Dept Hematol, Fukuoka 8111395, Japan
[3] Natl Canc Ctr, Stem Cell Transplantat Unit, Tokyo, Japan
[4] Imamura Bun In Hosp, Dept Hematol, Kagoshima, Japan
[5] Nagasaki Univ, Mol Med Unit, Dept Hematol, Atom Bomb Dis Inst,Sch Med, Nagasaki 852, Japan
[6] Kyushu Univ, Grad Sch Med Sci, Fukuoka 812, Japan
[7] Tokyo Med & Dent Univ, Div Med Res, Dept Immunotherapeut, Tokyo, Japan
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷 / 01期
基金：
日本学术振兴会;
关键词：
adult T-cell leukemia/lymphoma; allogeneic hematopoietic SCT; reduced-intensity conditioning regimen; HTLV-1 proviral load; RETROSPECTIVE ANALYSIS; LEUKEMIA-LYMPHOMA; TRANSPLANTATION; INTENSITY; IMPACT;
D O I：
10.1038/bmt.2010.92
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
We have previously conducted clinical trials of allogeneic hematopoietic SCT with reduced-intensity conditioning regimen (RIC) for adult T-cell leukemia/lymphoma (ATLL)-a disease caused by human T-lymphotropic virus type 1 (HTLV-1) infection and having a dismal prognosis. Long-term follow-up studies of these trials revealed that 10 of the 29 patients have survived for a median of 82 months (range, 54-100 months) after RIC, indicating a possible curability of the disease by RIC. However, we have also observed that the patterns of post-RIC changes in HTLV-1 proviral load over time among the 10 survivors were classified into three patterns. This is the first report to clarify the long-term outcomes after RIC for ATLL patients. Bone Marrow Transplantation (2011) 46, 116-118; doi:10.1038/bmt.2010.92; published online 19 April 2010
引用
收藏
页码：116 / 118
页数：3
相关论文
共 50 条
  • [11] A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma
    Hirose, Asao
    Koh, Hideo
    Nakamae, Mika
    Nakashima, Yasuhiro
    Nishimoto, Mitsutaka
    Okamura, Hiroshi
    Makuuchi, Yosuke
    Kuno, Masatomo
    Takakuwa, Teruhito
    Ido, Kentaro
    Sakatoku, Kazuki
    Hino, Masayuki
    Nakamae, Hirohisa
    BONE MARROW TRANSPLANTATION, 2024, 59 (05) : 695 - 698
  • [12] Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation
    Tanaka, Takashi
    Inamoto, Yoshihiro
    Ito, Ayumu
    Watanabe, Mizuki
    Takeda, Wataru
    Aoki, Jun
    Kim, Sung-Won
    Fukuda, Takahiro
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (03) : 389 - 395
  • [13] Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma
    Nosaka, Kisato
    Crawford, Bruce
    Yi, Jingbo
    Kuan, William
    Matsumoto, Tomoko
    Takahashi, Takeshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 108 (03) : 212 - 222
  • [14] Long-Term Survival of Patients with Adult T-Cell Leukemia/Lymphoma Treated with Amplified Natural Killer Cell Therapy
    Okubo, Yuji
    Nagai, Sho
    Katayama, Yuta
    Kitamura, Kunihiro
    Hiwaki, Kazuhisa
    Teshigawara, Keisuke
    REPORTS, 2024, 7 (03)
  • [15] Adult T-cell leukemia/lymphoma
    Bittencourt, Achilea L.
    Farre, Lourdes
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2008, 83 (04) : 351 - 359
  • [16] Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma
    Cook, Lucy B.
    Rowan, Aileen G.
    Demontis, Maria A.
    Sagawe, Sophie
    Gillet, Nicolas A.
    Melamed, Anat
    Greiller, Claire
    Witkover, Aviva
    Bangham, Charles R. M.
    Taylor, Graham P.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (03) : 378 - 382
  • [17] New treatments for adult T-cell leukemia/lymphoma
    Epstein-Peterson, Zachary D.
    Gurumurthi, Ashwath
    Horwitz, Steven M.
    LEUKEMIA RESEARCH, 2025, 149
  • [18] MOGAMULIZUMAB FOR THE TREATMENT OF ADULT T-CELL LEUKEMIA/LYMPHOMA
    de Lartigue, J.
    DRUGS OF TODAY, 2012, 48 (10) : 655 - 660
  • [19] Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma
    Beltran, Brady
    Quinones, Pilar
    Morales, Domingo
    Cotrina, Esther
    Castillo, Jorge J.
    LEUKEMIA RESEARCH, 2011, 35 (03) : 334 - 339
  • [20] Molecular Pathology of Adult T-Cell Leukemia/Lymphoma
    Ohshima, Koichi
    ONCOLOGY, 2015, 89 : 7 - 15
12345